TNF and infection: The safety of TNF antagonists in patients with fistulising disease is of concern, because of the greater risk of infection at baseline (especially abscesses) for these patients.15 In the CHARM fistula cohort, there were no differences in the rates of adverse events, including infectious adverse events and, specifically, abscesses, in patients who received placebo compared with those who received adalimumab at either dosage.